- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
Patent holdings for IPC class A61K 31/635
Total number of patents in this class: 1072
10-year publication summary
|
81
|
102
|
106
|
97
|
116
|
96
|
127
|
158
|
115
|
35
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 11238 |
15 |
| Dana-Farber Cancer Institute, Inc. | 2455 |
15 |
| The Johns Hopkins University | 5377 |
14 |
| Mayo Foundation for Medical Education and Research | 2981 |
14 |
| scPharmaceuticals Inc. | 27 |
13 |
| Board of Regents, The University of Texas System | 5370 |
12 |
| Virios Therapeutics, Inc. | 14 |
12 |
| Merck Sharp & Dohme LLC | 3689 |
10 |
| The Regents of the University of California | 18943 |
9 |
| Boehringer Ingelheim Vetmedica GmbH | 1290 |
9 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3314 |
9 |
| Abbvie Inc. | 1808 |
8 |
| Celgene Corporation | 1412 |
8 |
| Rigel Pharmaceuticals, Inc. | 613 |
8 |
| Esteve Pharmaceuticals, S.A. | 206 |
8 |
| Ascentage Pharma (Suzhou) Co., Ltd. | 153 |
8 |
| Genentech, Inc. | 3742 |
7 |
| AstraZeneca AB | 3042 |
7 |
| Sublimity Therapeutics Limited | 39 |
7 |
| Scilex Holding Company | 12 |
7 |
| Other owners | 872 |